More recently, it is also reported that sodium-glucose transport protein 2 (SGLT2) inhibitors interacts with hypoxia-inducible factors and may promote erythrocytosis.[24] Further studies would also be needed to delineate any additive or synergistic erythropoietic effects between DPP-4 inhibitor and SGLT2 inhibitor, both of which are increasingly used for the treatment of diabetes.[25]. Here, DPP4 is linked to diabetes mellitus.